title: Severity scoring systems for prognosis and efficacy of polymyxin B-immobilized fiber treatment for colonic perforation.
abstract: OBJECTIVE
  There is no established system for predicting prognosis and evaluating the efficacy of antiseptic treatments such as polymyxin B-immobilized fiber (PMX) according to the severity of peritonitis in patients with colonic perforation. We investigated the predictive value of various severity scoring systems for survival and for the efficacy of antiseptic treatments, to identify high-risk patients.
  
  
  METHODS
  We reviewed 26 consecutive patients who underwent emergency operations between 1996 and 2003 for colorectal perforation not caused by trauma or iatrogenic disease. Several severity scores, i.e., Acute Physiology and Chronic Health Evaluation II (APACHE II), Sequential Organ Failure Assessment (SOFA), Mannheim Peritonitis Index (MPI), and Multiple Organ Failure (MOF) were calculated and analyzed as predictive scoring systems for prognosis, survival and efficacy of PMX treatment.
  
  
  RESULTS
  An APACHE II score of 19, a SOFA score of 8, an MPI score of 30, and an MOF score of 7 or more were significantly related to a poor prognosis. With or without PMX treatment, an APACHE II score of 15 or less, a SOFA score of 7 or less, an MPI score of 27 or less, and an MOF score of 7 or less were all related to a good prognosis. Conversely, all patients died when the severity scoring points were higher than 20 in APACHE II, higher than 12 in SOFA, and higher than 39 in MPI. When PMX treatment was given to patients with an intermediate score, no correlation between survival and its efficacy was found, except in the MOF scoring system.
  
  
  CONCLUSIONS
  These severity scoring systems can assist with the prediction of prognosis. They may also be useful for determining if PMX treatment would be unnecessary or ineffective in certain patients. However, the optimal application of PMX treatment in selected patients according to the severity scoring systems needs further investigation.
authors.affiliation: Department of Surgery, Nagahama Red Cross Hospital, Nagahama, Shiga, Japan.
authors.forename: Shuhei
authors.initials: S
authors.lastname: Komatsu
authors.forename: Takumi
authors.initials: T
authors.lastname: Shimomatsuya
authors.forename: Masayuki
authors.initials: M
authors.lastname: Nakajima
authors.forename: Susumu
authors.initials: S
authors.lastname: Ono
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Maruhashi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D003106:Colon / Q000293:injuries* / Q000473:pathology; D005260:Female; D006801:Humans; D007416:Intestinal Perforation / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010538:Peritonitis / Q000145:classification* / Q000209:etiology; D011112:Polymyxin B / Q000627:therapeutic use*; D011379:Prognosis; D011446:Prospective Studies; D012306:Risk; D018805:Sepsis / Q000188:drug therapy* / Q000209:etiology; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D011112:Polymyxin B